Combination chemotherapy including Adriamycin for advanced transitional cell carcinoma of the urinary tract
β Scribed by Toshihiko Kotake; Michiyuki Usami; Tsuneharu Miki; Masao Kuroda; Koji Obata; Masao Osafune; Hideki Fujioka; Yutaka Takasugi
- Publisher
- Springer
- Year
- 1983
- Tongue
- English
- Weight
- 493 KB
- Volume
- 11
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Twenty patients with locally advanced and/or metastatic transitional cell cancer of the urinary tract were treated with cyclophosphamide 500 mg/m2, Adriamycin (doxorubicin) 40 mg/m2 and cis-platinum (CDDP) 40 mg/m2 given every three weeks for 2 cycles, alternating with methotrexate 40 mg/m2 weekly f
Activity has been demonstrated for both single agents and combination chemotherapy in advanced transitional cell carcinoma of the uroepithelium. Regimens are palliative; duration of response has been modest, usually ranging from 3 to 8 months. There are few complete responders; occasional patients r
## Abstract ## BACKGROUND Cisplatinβbased combinations are considered to be the standard treatment for advanced transitional cell carcinoma (TCC) of the urothelium. Many of the patients are elderly with concomitant diseases or impaired renal function. We studied the tolerance and activity of the g